PMC:7601109 / 89398-90331 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T167","span":{"begin":617,"end":622},"obj":"Body_part"},{"id":"T168","span":{"begin":915,"end":920},"obj":"Body_part"}],"attributes":[{"id":"A167","pred":"uberon_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A168","pred":"uberon_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T784","span":{"begin":542,"end":548},"obj":"Body_part"},{"id":"T785","span":{"begin":605,"end":611},"obj":"Body_part"},{"id":"T786","span":{"begin":617,"end":622},"obj":"Body_part"},{"id":"T787","span":{"begin":832,"end":838},"obj":"Body_part"},{"id":"T788","span":{"begin":897,"end":903},"obj":"Body_part"},{"id":"T789","span":{"begin":915,"end":920},"obj":"Body_part"}],"attributes":[{"id":"A784","pred":"fma_id","subj":"T784","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A785","pred":"fma_id","subj":"T785","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A786","pred":"fma_id","subj":"T786","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A787","pred":"fma_id","subj":"T787","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A788","pred":"fma_id","subj":"T788","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A789","pred":"fma_id","subj":"T789","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T147","span":{"begin":211,"end":221},"obj":"Disease"}],"attributes":[{"id":"A147","pred":"mondo_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/MONDO_0006516"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1563","span":{"begin":36,"end":41},"obj":"http://purl.obolibrary.org/obo/CLO_0007735"},{"id":"T1564","span":{"begin":173,"end":177},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T1565","span":{"begin":173,"end":177},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T1566","span":{"begin":194,"end":195},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1567","span":{"begin":196,"end":201},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T1568","span":{"begin":489,"end":497},"obj":"http://purl.obolibrary.org/obo/CL_0002372"},{"id":"T1569","span":{"begin":529,"end":531},"obj":"http://purl.obolibrary.org/obo/CLO_0008954"},{"id":"T1570","span":{"begin":533,"end":548},"obj":"http://purl.obolibrary.org/obo/UBERON_0001134"},{"id":"T1571","span":{"begin":533,"end":548},"obj":"http://purl.obolibrary.org/obo/UBERON_0014892"},{"id":"T1572","span":{"begin":533,"end":548},"obj":"http://www.ebi.ac.uk/efo/EFO_0000888"},{"id":"T1573","span":{"begin":605,"end":611},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T1574","span":{"begin":605,"end":611},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T1575","span":{"begin":605,"end":611},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T1576","span":{"begin":605,"end":611},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"},{"id":"T1577","span":{"begin":652,"end":654},"obj":"http://purl.obolibrary.org/obo/CLO_0008954"},{"id":"T1578","span":{"begin":699,"end":707},"obj":"http://purl.obolibrary.org/obo/CL_0002372"},{"id":"T1579","span":{"begin":716,"end":726},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1580","span":{"begin":809,"end":811},"obj":"http://purl.obolibrary.org/obo/CLO_0008954"},{"id":"T1581","span":{"begin":823,"end":838},"obj":"http://purl.obolibrary.org/obo/UBERON_0001134"},{"id":"T1582","span":{"begin":823,"end":838},"obj":"http://purl.obolibrary.org/obo/UBERON_0014892"},{"id":"T1583","span":{"begin":823,"end":838},"obj":"http://www.ebi.ac.uk/efo/EFO_0000888"},{"id":"T1584","span":{"begin":888,"end":903},"obj":"http://purl.obolibrary.org/obo/UBERON_0001134"},{"id":"T1585","span":{"begin":888,"end":903},"obj":"http://purl.obolibrary.org/obo/UBERON_0014892"},{"id":"T1586","span":{"begin":888,"end":903},"obj":"http://www.ebi.ac.uk/efo/EFO_0000888"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T81784","span":{"begin":72,"end":83},"obj":"Chemical"},{"id":"T453","span":{"begin":173,"end":177},"obj":"Chemical"},{"id":"T454","span":{"begin":236,"end":247},"obj":"Chemical"},{"id":"T59524","span":{"begin":336,"end":347},"obj":"Chemical"}],"attributes":[{"id":"A80516","pred":"chebi_id","subj":"T81784","obj":"http://purl.obolibrary.org/obo/CHEBI_78665"},{"id":"A15568","pred":"chebi_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A55600","pred":"chebi_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/CHEBI_78665"},{"id":"A60001","pred":"chebi_id","subj":"T59524","obj":"http://purl.obolibrary.org/obo/CHEBI_78665"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T569","span":{"begin":0,"end":39},"obj":"Sentence"},{"id":"T570","span":{"begin":40,"end":629},"obj":"Sentence"},{"id":"T571","span":{"begin":631,"end":933},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2780","span":{"begin":502,"end":505},"obj":"Gene"},{"id":"2781","span":{"begin":623,"end":628},"obj":"Gene"},{"id":"2782","span":{"begin":730,"end":733},"obj":"Gene"},{"id":"2783","span":{"begin":909,"end":914},"obj":"Gene"},{"id":"2891","span":{"begin":186,"end":190},"obj":"Species"},{"id":"2892","span":{"begin":196,"end":201},"obj":"Species"},{"id":"2893","span":{"begin":318,"end":322},"obj":"Species"},{"id":"2894","span":{"begin":379,"end":383},"obj":"Species"},{"id":"2895","span":{"begin":433,"end":437},"obj":"Species"},{"id":"3035","span":{"begin":211,"end":221},"obj":"Disease"}],"attributes":[{"id":"A2780","pred":"tao:has_database_id","subj":"2780","obj":"Gene:11651"},{"id":"A2781","pred":"tao:has_database_id","subj":"2781","obj":"Gene:16000"},{"id":"A2782","pred":"tao:has_database_id","subj":"2782","obj":"Gene:11651"},{"id":"A2783","pred":"tao:has_database_id","subj":"2783","obj":"Gene:16000"},{"id":"A2891","pred":"tao:has_database_id","subj":"2891","obj":"Tax:10090"},{"id":"A2892","pred":"tao:has_database_id","subj":"2892","obj":"Tax:10090"},{"id":"A2893","pred":"tao:has_database_id","subj":"2893","obj":"Tax:10090"},{"id":"A2894","pred":"tao:has_database_id","subj":"2894","obj":"Tax:10090"},{"id":"A2895","pred":"tao:has_database_id","subj":"2895","obj":"Tax:10090"},{"id":"A3035","pred":"tao:has_database_id","subj":"3035","obj":"MESH:D055948"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In vitroRoyal jelly and pRJ (500 μg/mL: 1, 2, 3, and 5 d)In vivoDietary royal jelly and pRJ (1% and 5% for 3 months) In vitroSC isolated from aged miceIn vivo21-months old male C57BL/6 mice as a mouse model of sarcopenia In vitroEG1: royal jelly treated SCEG2: pRJ treated SCCG: untreated SCIn vivoEG1 and EG2: aged mice on 1% and 5% royal jelly, respectivelyEG3 and EG4: aged mice on 1% and 5% pRJ, respectivelyCG: untreated aged mice In vitroSC proliferation and differentiation into myotubes and AKT signaling.In vivoNo of SC, skeletal muscle weight, grip strength, regenerative capacity of injured muscle, and serum IGF-1. In vitropRJ enhanced SC proliferation rate and differentiation into myotubes through activation of AKT signaling.In vivoRoyal jelly and pRJ significantly increased the number of SC, weight of skeletal muscle, grip strength, regenerative capacity of injured skeletal muscle, and IGF-1 serum level. [96]"}